VEGFR-2 DNA Vaccine VXM01
Semantic Scholar uses AI to extract papers important to this topic.
ABSTRACT VXM01 is a first-in-kind orally applied tumor vaccine based on live attenuated Salmonella typhi carrying an expression… Expand AIM
To investigate possible associations between VEGFR-2 and IL-8 gene SNPs and 1-year response to intravitreal ranibizumab for… Expand Aim:The current therapeutic approaches have a limited effect on the dysregulated pulmonary vascular remodeling, which is… Expand Aim:Nanobody is an antibody fragment consisting of a single monomeric variable antibody domain, which can be used for a variety… Expand 3091Background: VXM01 is an orally applied tumor vaccine based on live, attenuated salmonella bacteria carrying a eukaryotic… Expand VEGFR-2 is expressed on tumor vasculature and a target for anti-angiogenic intervention. VXM01 is a first in kind orally applied… Expand BackgroundThe investigational oral DNA vaccine VXM01 targets the vascular endothelial growth factor receptor 2 (VEGFR-2) and uses… Expand Dhakal H P, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky K‐E… Expand It is not well‐understood how low‐laser therapy affects the skin of the applied area. This study analyzes skin of the masseteric… Expand BACKGROUND: Endothelial progenitor cells (EPCs) have been identified among hematopoietic tissue‐derived progenitor cells that are… Expand